tirzepatide chronic kidney disease trial and prevention of 🧬 New data from the

In December 2024, the FDA abruptly determined that the tirzepatide shortage had resolved and removed these products from its shortage list, effectively terminating compounders' legal authority to produce these drugs

GLP-2TZ is a synthetic 39-amino-acid peptide engineered as a dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R)

September 2024: There has been an explosion of new lawsuits filed into the MDL over the last month as Ozempic litigation expands

Cosmetic fillers or skin tightening procedures can help minimize the appearance of wrinkles or sagging skin, Dr

Relationship between body weight change and glycemic control with tirzepatide treatment in people with type 2 diabetes (abstract) Diabetes

Lower doses are where most patients start